Abstract
Renal transplantation is the preferred treatment of ESKD, but the shortage of suitable donor kidneys from the cadaver pool means that many patients with ESKD will not receive a kidney transplant. Xenotransplantation has long represented a solution to the kidney shortage, but the occurrence of antibody-mediated rejection has precluded its clinical development. Developments in somatic cell nuclear transfer in pigs and gene editing tools have led to the creation of new donor pigs with greatly improved crossmatches to patients. In addition, improvements in preclinical kidney xenotransplant survival using new anti-CD40/CD154-based immunosuppression have pushed xenotransplantation to the point where it is reasonable to consider initiating a clinical trial to evaluate this potential therapy in patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 278-284 |
| Number of pages | 7 |
| Journal | Kidney360 |
| Volume | 4 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2023 |
Bibliographical note
Funding Information:A.J. Tector was supported by National Institute of Allergy and Infectious Diseases, National Institutes of Health, grants U01AI126322 and 5U19AI142737.
Publisher Copyright:
© 2022 by the American Society of Nephrology.
Keywords
- basic science
- transplantation
- xenotransplantation
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural